Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data

INTRODUCTION: Nivolumab has been approved in patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. A pivotal trial compared nivolumab with ipilimumab; however, no head-to-head trial exists comparing nivolumab to obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Morganna, Betts, Keith A., Jiang, Shan, Du, Ella X., Gupte-Singh, Komal, Lu, Yichen, Rao, Sumati, Shoushtari, Alexander N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822822/
https://www.ncbi.nlm.nih.gov/pubmed/31440980
http://dx.doi.org/10.1007/s12325-019-01060-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822822/
https://www.ncbi.nlm.nih.gov/pubmed/31440980
http://dx.doi.org/10.1007/s12325-019-01060-y

Ejemplares similares